Eli Lilly Acquires Curevo (Shingles) and LimmaTech Biologics (Bacterial Vaccines)
May 26, 2026
Eli Lilly entered definitive agreements to acquire Curevo Vaccine and LimmaTech Biologics as part of a broader expansion of its infectious disease R&D platform. Lilly will acquire Curevo for up to $1.5 billion and LimmaTech Biologics for up to $780 million, with upfront and additional milestone-based payments.
- Buyers
- Eli Lilly and Company
- Targets
- Curevo Vaccine (Curevo), LimmaTech Biologics AG (LimmaTech Biologics)
- Industry
- Pharmaceuticals
- Location
- Switzerland
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.